Basal continuous subcutaneous insulin infusion (CSII) therapy at a fixed rate may effectively improve glycemic control in patients with type 2 diabetes when oral antidiabetic treatment fails. Regimens of simple constant subcutaneous delivery of insulin may provide theoretical advantages in type 2 diabetes.
Methods:
Ten subjects with type 2 diabetes who obtained insufficient glycemic control on oral antidiabetic drugs were included. Following an initial control day, two periods of 3 days with CSII of a rapid-acting insulin analogue, 1.5 IU/h (dose obtained from a preceding study), for 8 hours overnight and for 24 hours, respectively, were carried out in random order. Profiles of serum insulin aspart, serum endogenous insulin, and plasma glucose were recorded.
Results:
Compared to the control day, an 8-hour overnight insulin infusion during a 3-day period improved fasting plasma glucose (FPG) (mean differences ± SEM; Δ59.0 ± 10.1 mg/dl; p < 0.01) and 2-hour postprandial plasma glucose (PPPG) (Δ57.8 ± 10.6 mg/dl; p < 0.01) after breakfast. Compared to an 8-hour overnight infusion, a 24-hour infusion further improved all three PPPG values after breakfast, lunch, and dinner (Δ28.8 ± 8.1 mg/dl, Δ30.6 ± 8.1 mg/dl, and Δ35.1 ± 7.9 mg/dl; p < 0.01). During insulin infusion, only one hypoglycemic episode with PG <55.8 mg/dl and mild symptoms was recorded.
Conclusion:
Continuous subcutaneous insulin infusion with a rapid-acting insulin analogue at a fixed rate of 1.5 IU/h, either overnight or for 24 hours, improved glycemic control without safety concerns in patients with type 2 diabetes who had secondary failure to oral antidiabetic drugs. The effect on FPG was similar for both treatments, whereas the effect on PPPG was superior when insulin was infused during the entire 24 hours.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837–53.
2.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854–65.
3.
StrattonIMAdlerAINeilHAMatthewsDRManleySECullCAHaddenDTurnerRCHolmanRR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321: 405–12.
4.
ShichiriMKishikawaHOhkuboYWakeN. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23Suppl 2: B21–9.
5.
LevyJAtkinsonABBellPMMcCanceDRHaddenDR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998; 15: 290–6.
6.
HolmanRR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Prac. 1998; 40Suppl: S21–5.
7.
GroopLCPelkonenRKoskimiesSBottazzoGFDoniachD. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care. 1986; 9: 129–33.
8.
WrightABurdenACPaiseyRBCullCAHolmanRR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002; 25: 330–6.
9.
European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999; 16: 716–30.
10.
DavisTEdelmanSV. Insulin therapy in type 2 diabetes. Med Clin North Am. 2004; 88: 865–95.
11.
PuhakainenITaskinenMRYki-JarvinenH. Comparison of acute daytime and nocturnal insulinization on diurnal glucose homeostasis in NIDDM. Diabetes Care. 1994; 17: 805–9.
12.
Yki-JarvinenHKauppilaMKujansuuELahtiJMarjanenTNiskanenLRajalaSRyysyLSaloSSeppalaP. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992; 327: 1426–33.
13.
StarkeAAHeinemannLHohmannABergerM. The action profiles of human NPH insulin preparations. Diabet Med. 1989; 6: 239–44.
14.
RaslovaKBogoevMRazILethGGallMAHancuN. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004; 66: 193–201.
15.
OwensDRCoatesPALuzioSDTinbergenJPKurzhalsR. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000; 23: 813–9.
16.
HeiseTNosekLRonnBBEndahlLHeinemannLKapitzaCDraegerE. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53: 1614–20.
17.
KleinOLyngeJEndahlLDamholtBNosekLHeiseT. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007; 9: 290–9.
18.
LauritzenT. Pharmacokinetic and clinical aspects of intensified subcutaneous insulin therapy. Dan Med Bull. 1985; 32: 104–18.
19.
HermansenKDaviesMDerezinskiTMartinezRGClausonPHomeP. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006; 29: 1269–74.
20.
RiddleMCRosenstockJGerichJ. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080–6.
21.
DuckworthWDavisSN. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications. 2007; 21: 196–204.
22.
WainsteinJMetzgerMBoazMMinuchinOCohenYYaffeAYerushalmyYRazIHarman-BoehmI. Insulin pump therapy vs. multiple daily injections in obese type 2 diabetic patients. Diabet Med. 2005; 22: 1037–46.
23.
ParknerTMollerMKChenJWLaursenTJorgensenCSmedegaardJSLauritzenTChristiansenJS. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes. Diabetes Obes Metab. 2007 Jun 26 (online early).
24.
SenstiusJ.HarboeE.WestermannH.In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump. Diabetes Technol Ther. 2007; 9: 75–9.
25.
McLeanMHRyanWTHearnDJ. Comparison of the Beckman oxygen rate glucose method to a national reference and other methods. Am J Med Technol. 1977; 43: 164–6.
26.
AndersenLDinesenBJorgensenPNPoulsenFRoderME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem. 1993; 39: 578–82.
27.
AndersenLJorgensenPNJensenLBWalshD. A new insulin immunoassay specific for the rapid-acting insulin analog, insulin aspart, suitable for bioavailability, bioequivalence, and pharmacokinetic studies. Clin Biochem. 2000; 33: 627–33.
28.
ZangenehFAroraPSDyckPJBekrisLLernmarkAAchenbachSJObergALRizzaRA. Effects of duration of type 2 diabetes mellitus on insulin secretion. Endocr Pract. 2006; 12: 388–93.
29.
GarveyWTOlefskyJMGriffinJHammanRFKoltermanOG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985; 34: 222–34.
30.
LiYXuWLiaoZYaoBChenXHuangZHuGWengJP. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004; 27: 2597–602.
31.
LeporeMPampanelliSFanelliCPorcellatiFBartocciLDi VincenzoACordoniCCostaEBrunettiPBolliGB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49: 2142–8.
32.
RaskinPBodeBWMarksJBHirschIBWeinsteinRLMcGillJBPetersonGEMudaliarSRReinhardtRR. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003; 26: 2598–603.
33.
HoogmaRPHammondPJGomisRKerrDBruttomessoDBouterKPWiefelsKJde la CalleHSchweitzerDHPfohlMTorloneEKrinelkeLGBolliGB; 5-Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med. 23: 141–7.
34.
HirschIBBodeBWGargSLaneWSSussmanAHuPSantiagoOMKolaczynskiJW. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005; 28: 533–8.
